Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Open accessThe DOI matches its Crossref record; 284 of the 284 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression. In this review, we first provide an update on how the risk factors, including APOE variants, infections and inflammation, contribute to AD; how Aβ and tau become abnormally accumulated and how this accumulation plays a role in AD neurodegeneration. Then we summarize the commonly used experimental models, diagnostic and prediction strategies, and advances in periphery biomarkers from high-risk populations for AD. Finally, we introduce current status of development of disease-modifying drugs, including the newly officially approved Aβ vaccines, as well as novel and promising strategies to target the abnormal pTau. Together, this paper was aimed to update AD research progress from fundamental mechanisms to the clinical diagnosis and therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–284 of 284
Prion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target
Holmes, B. B., & Diamond, M. I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.549295 · Cited by 202
Wilcock, D. M., Munireddy, S. K., Rosenthal, A., Ugen, K. E., Gordon, M. N., & Morgan, D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.015 · Cited by 202
Cell type‐specific roles of APOE4 in Alzheimer disease
Blumenfeld, J., Yip, O., Kim, M. J., & Huang, Y. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00776-9 · Cited by 202 · cited 3×
“In microglia, APOE promotes Aβ degradation via neprilysin and APOE4 exhibits the lowest ability among the three isoforms [54].”
BackgroundInfluentialThe Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology
Cotman, C. W., Poon, W. W., Rissman, R. A., & Blurton-Jones, M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.104 · Cited by 199
Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition
Rodriguez, G. A., Tai, L. M., LaDu, M. J., & Rebeck, G. W. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-111 · Cited by 193
Alzheimer’s disease can be accurately diagnosed in very mildly impaired individuals
Salmon, D. P., Thomas, R. G., Pay, M. M., Booth, A., Hofstetter, C. R., Thal, L. J., & Katzman, R. (2002) · Neurology · doi:10.1212/wnl.59.7.1022 · Cited by 189 · cited 1×
“Evaluating cognitive function comprehensively allows for a better understanding of patients’ cognitive status and characteristics, which plays an essential role in the diagnosis, subtyping, and etiological analysis of cognitive impairment and dementia [528].”
BackgroundJi, Y., Gong, Y., Gan, W., Beach, T., Holtzman, D. M., & Wisniewski, T. (2003) · Neuroscience · doi:10.1016/j.neuroscience.2003.08.007 · Cited by 189
Caspase-2 cleavage of tau reversibly impairs memory
Zhao, X., Kotilinek, L. A., Smith, B., Hlynialuk, C., Zahs, K., Ramsden, M., Cleary, J., & Ashe, K. H. (2016) · Nature Medicine · doi:10.1038/nm.4199 · Cited by 187 · cited 1×
“Tau truncated at Asp314 by caspase-2 results in mislocation of tau into the dendritic spines and impairs the function of postsynaptic membrane glutamate receptors [432, 437], although it is also reported that the Asp314 truncation exhibits anti-aggregation properties [432, 437].”
BackgroundBennecib, M., Gong, C.-X., Grundke-Iqbal, I., & Iqbal, K. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02203-1 · Cited by 184 · cited 1×
“Okadaic acid (OA, Ki 100 nM) and calyculin A (CA, Ki 50 nM) can also inhibit PP1 [368].”
BackgroundTai, L. M., Bilousova, T., Jungbauer, L., Roeske, S. K., Youmans, K. L., Yu, C., Poon, W. W., Cornwell, L. B., Miller, C. A., Vinters, H. V., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442103 · Cited by 165 · cited 1×
“In APP transgenic mice, APOE4 can form a stable complex with Aβ that is resistant to degradation [82].”
BackgroundMiklossy, J., Khalili, K., Gern, L., Ericson, R. L., Darekar, P., Bolle, L., Hurlimann, J., & Paster, B. J. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6608 · Cited by 163 · cited 1×
“Spirochetes are Gram-negative spiral bacteria with internal flagella that can invade the brain and establish latent and persistent infections [135].”
BackgroundApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease
Lane-Donovan, C., & Herz, J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.12.001 · Cited by 157 · cited 1×
“VLDL-R and LDL-R are predominantly located on the astrocyte membrane, while LRP is mainly distributed in neurons and activated astrocytes [45].”
BackgroundRecent advances in the modeling of Alzheimer’s disease
Sasaguri, H., Hashimoto, S., Watamura, N., Sato, K., Takamura, R., Nagata, K., Tsubuki, S., Ohshima, T., Yoshiki, A., Sato, K., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.807473 · Cited by 157
Cowan, C. M., Bossing, T., Page, A., Shepherd, D., & Mudher, A. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0716-8 · Cited by 156
Controversy and Progress in Alzheimer’s Disease — FDA Approval of Aducanumab
Rabinovici, G. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmp2111320 · Cited by 155 · cited 1×
“Aducanumab, a monoclonal antibody targeting Aβ developed by Eisai/Biogen, was first conditionally approved by the U.S. Food and Drug Administration (FDA) in June 2021 [583].”
BackgroundAnimal models of Alzheimer’s disease: Applications, evaluation, and perspectives
Chen, Z.-Y., 北京大学生命科学学院膜生物学国家重点实验室, 北. 1., State Key Laboratory of Membrane Biology, C. O. L. S., & Zhang, Y. (2022) · Zoological Research · doi:10.24272/j.issn.2095-8137.2022.289 · Cited by 155 · cited 1×
“In recent years, scientists have attempted to establish AD patient-derived cell and organoid models that better simulate their brain pathology [472].”
BackgroundSelf-citationInteraction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease
Linard, M., Letenneur, L., Garrigue, I., Doize, A., Dartigues, J., & Helmer, C. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12008 · Cited by 152
RNA binding proteins co-localize with small tau inclusions in tauopathy
Maziuk, B. F., Apicco, D. J., Cruz, A. L., Jiang, L., Ash, P. E. A., da Rocha, E. L., Zhang, C., Yu, W. H., Leszyk, J., Abisambra, J. F., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0574-5 · Cited by 151
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Self-citationThe microtubule-associated tau protein has intrinsic acetyltransferase activity
Cohen, T. J., Friedmann, D., Hwang, A. W., Marmorstein, R., & Lee, V. M. Y. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2555 · Cited by 149 · cited 2×
“Lee’s group found that tau protein possesses acetyl-transferase activity that can catalyze self-acetylation [285].”
BackgroundWhittaker, D. S., Akhmetova, L., Carlin, D., Romero, H., Welsh, D. K., Colwell, C. S., & Desplats, P. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.014 · Cited by 147 · cited 1×
“Non-pharmacological treatments encompass dietary adjustments [603] (e.g., Mediterranean diet or time-restricted feeding) [604, 605], cognitive training [606], physical exercise [607, 608], music therapy [609], etc.”
BackgroundInhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer’s disease
Zhang, Z., Obianyo, O., Dall, E., Du, Y., Fu, H., Liu, X., Kang, S. S., Song, M., Yu, S.-P., Cabrele, C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14740 · Cited by 146 · cited 1×
“This AEP-mediated APP cleavage is also termed as the δ-secretase pathway [168–170].”
BackgroundSelf-citationLiu, C.-C., Wang, N., Chen, Y., Inoue, Y., Shue, F., Ren, Y., Wang, M., Qiao, W., Ikezu, T. C., Li, Z., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01640-9 · Cited by 146
Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading
Jain, N., Lewis, C. A., Ulrich, J. D., & Holtzman, D. M. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220654 · Cited by 146
Oskar Fischer and the study of dementia
Goedert, M. (2008) · Brain · doi:10.1093/brain/awn256 · Cited by 144 · cited 1×
“The hypothesis that AD may be caused by pathogenic infections was initially proposed by Dr. Oskar Fischer in 1907 [113].”
BackgroundRichard, B. C., Kurdakova, A., Baches, S., Bayer, T. A., Weggen, S., & Wirths, O. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143120 · Cited by 142 · cited 1×
“(2) Models simultaneously expressing mutated APP and PSEN1 genes The PS/APP (AβPPSwe/PS1M146L) [488, 489], 2KI (AβPPSwe/PS1P264L) [490] and 5 × FAD (AβPPSwe, Lnd, Flo/PS1M146L, L286V) [491, 492] are the most commonly used models [474, 493].”
BackgroundFunk, K. E., Thomas, S. N., Schafer, K. N., Cooper, G. L., Liao, Z., Clark, D. J., Yang, A. J., & Kuret, J. (2014) · Biochemical Journal · doi:10.1042/bj20140372 · Cited by 142 · cited 2×
“The in vitro methylated tau appears to have reduced aggregation tendencies and can promote tubulin assembly, hinting at a protective role against protein aggregation [405].”
BackgroundBeffert, U., Cohn, J. S., Petit-Turcotte, C., Tremblay, M., Aumont, N., Ramassamy, C., Davignon, J., & Poirier, J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01894-6 · Cited by 142 · cited 1×
“For example, damage to the olfactory cortex results in the loss of approximately 60% of synaptic inputs to the granule cell layer of the hippocampus, but new synapses can be formed from the sprouting of surviving axons [40].”
BackgroundAPOE ε2 is associated with increased tau pathology in primary tauopathy
Zhao, N., Liu, C.-C., Van Ingelgom, A. J., Linares, C., Kurti, A., Knight, J. A., Heckman, M. G., Diehl, N. N., Shinohara, M., Martens, Y. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06783-0 · Cited by 139 · cited 2×
“However, there is still controversy on the effect of APOEε2 on tau [100, 102– 104].”
BackgroundKontaxi, C., Piccardo, P., & Gill, A. C. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00056 · Cited by 138
Mahan, T. E., Wang, C., Bao, X., Choudhury, A., Ulrich, J. D., & Holtzman, D. M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00516-0 · Cited by 134 · cited 1×
“Removal of APOE4 results in the disappearance of Congo red-stained Aβ plaque-like structures, while reintroducing APOE4 leads to the formation of senile plaques [83, 84].”
BackgroundFAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction
Flood, D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00330-x · Cited by 131
β-Amyloid (Aβ) Deposition in the Brains of Aged Orangutans
Gearing, M., Tigges, J., Mori, H., & Mirra, S. S. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00012-2 · Cited by 130
Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody
Yuzwa, S. A., Yadav, A. K., Skorobogatko, Y., Clark, T., Vosseller, K., & Vocadlo, D. J. (2011) · Amino Acids · doi:10.1007/s00726-010-0705-1 · Cited by 130 · cited 1×
“There are conflicting reports regarding the relationship between O-glycosylation and phosphorylation of tau protein [411, 412].”
BackgroundCorsetti, V., Florenzano, F., Atlante, A., Bobba, A., Ciotti, M. T., Natale, F., Della Valle, F., Borreca, A., Manca, A., Meli, G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv059 · Cited by 129
Gut microbiota regulates blood‐cerebrospinal fluid barrier function and Aβ pathology
Xie, J., Bruggeman, A., De Nolf, C., Vandendriessche, C., Van Imschoot, G., Van Wonterghem, E., Vereecke, L., & Vandenbroucke, R. E. (2023) · The EMBO Journal · doi:10.15252/embj.2022111515 · Cited by 125
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124 · cited 1×
“The proportion of APOE2 in long-lived elderly European and American populations is almost twice that of the general life-span population, while the frequency of APOE2 allele in AD patients is extremely low [53].”
BackgroundThomas, S. N., Funk, K. E., Wan, Y., Liao, Z., Davies, P., Kuret, J., & Yang, A. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0893-0 · Cited by 123
Cooper, J. M., Lathuiliere, A., Migliorini, M., Arai, A. L., Wani, M. M., Dujardin, S., Muratoglu, S. C., Hyman, B. T., & Strickland, D. K. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100715 · Cited by 122 · cited 1×
“…high affinity to tau at the micro-tubule-binding domain of tau, while phosphorylation of tau inhibits the associations between tau and LRP1 and thus decreases the internalization of extracellular tau proteins, which may play a role in the spreading of the pathological tau in the AD brains [110].”
BackgroundNelson, M. R., Liu, P., Agrawal, A., Yip, O., Blumenfeld, J., Traglia, M., Kim, M. J., Koutsodendris, N., Rao, A., Grone, B., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01480-8 · Cited by 120 · cited 1×
“A recent whole-exome sequencing study revealed an additional rare homozygous mutation of APOE 3 (APOE3ch, R136S) as the potential protective factor against AD [105].”
BackgroundAPOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread
Chen, Y., Song, S., Parhizkar, S., Lord, J., Zhu, Y., Strickland, M. R., Wang, C., Park, J., Tabor, G. T., Jiang, H., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.029 · Cited by 120 · cited 1×
“APOE3ch expression alleviated Aβ deposition, tau pathology, astrogliosis, and cell death, with the mechanisms involving an increased myeloid cell phagocytosis [107, 108].”
BackgroundZhong, S., & Khalil, R. A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.033 · Cited by 119
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia
Mühlbauer, V., Möhler, R., Dichter, M. N., Zuidema, S. U., Köpke, S., & Luijendijk, H. J. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013304.pub2 · Cited by 117
Extracellular Monomeric Tau Is Internalized by Astrocytes
Perea, J. R., López, E., Díez-Ballesteros, J. C., Ávila, J., Hernández, F., & Bolós, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00442 · Cited by 114 · cited 1×
“In astrocytes, uptake of tau-containing exosomes has not been detected [462]; instead, non-HSPG-dependent endocytosis of tau proteins has been shown [467].”
BackgroundNimgaonkar, V. L., Yolken, R. H., Wang, T., Chang, C.-C. H., McClain, L., McDade, E., Snitz, B. E., & Ganguli, M. (2016) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000133 · Cited by 109 · cited 1×
“Epidemiological data show that exposure to Toxoplasma gondii , cytomegalovirus, or HSV-2 is associated with cognitive decline in the elder population [127].”
BackgroundDeng, Y., Wang, Z., Wang, R., Zhang, X., Zhang, S., Wu, Y., Staufenbiel, M., Cai, F., & Song, W. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12235 · Cited by 108 · cited 2×
“(1) Amyloidogenic pathway β-Secretase, referred to as β-site APP-cleaving enzyme-1 (BACE1), cleaves APP695 at Asp1 between Met596 and Asp597, resulting in the release of 99-aa residue membrane-associated C-terminal fragment (CTF or C99) [164–166].”
BackgroundFurther understanding the connection between Alzheimer's disease and Down syndrome
Snyder, H. M., Bain, L. J., Brickman, A. M., Carrillo, M. C., Esbensen, A. J., Espinosa, J. M., Fernandez, F., Fortea, J., Hartley, S. L., Head, E., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12112 · Cited by 105
The cell biology of APOE in the brain
Windham, I. A., & Cohen, S. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.09.004 · Cited by 103 · cited 1×
“The secondary structure of the APOE proteins includes α-helices, β-sheets, β-turns, and irregular structures with two distinct regions: the receptor-binding region in the N-terminal and the lipid-binding region in the C-terminal [35].”
BackgroundTrzeciakiewicz, H., Ajit, D., Tseng, J.-H., Chen, Y., Ajit, A., Tabassum, Z., Lobrovich, R., Peterson, C., Riddick, N. V., Itano, M. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19317-4 · Cited by 102 · cited 1×
“In addition, tau can bind microfilament (such as actin), tyrosine kinase (such as Fyn and Src) [299] in the synapses, histone deacetylase-6 [300], APOE, and other molecules [301–305], by which it affects down-stream signaling pathways and cell functions.”
BackgroundErcan-Herbst, E., Ehrig, J., Schöndorf, D. C., Behrendt, A., Klaus, B., Gomez Ramos, B., Prat Oriol, N., Weber, C., & Ehrnhoefer, D. E. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0823-2 · Cited by 101 · cited 2×
“It is also reported that phosphorylation of tau at S198, S199, S416, S396, and S422 correlates with increased oligomerization or increased aggregation of tau proteins [383].”
BackgroundHu, Z., Chen, P.-H., Li, W., Douglas, T., Hines, J., Liu, Y., & Crews, C. M. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11706 · Cited by 98
Perez, S. E., Raghanti, M. A., Hof, P. R., Kramer, L., Ikonomovic, M. D., Lacor, P. N., Erwin, J. M., Sherwood, C. C., & Mufson, E. J. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23428 · Cited by 95 · cited 2×
“NHPs show close genetic homology to humans [484, 485, 487].”
BackgroundSepulveda-Falla, D., Sanchez, J. S., Almeida, M. C., Boassa, D., Acosta-Uribe, J., Vila-Castelar, C., Ramirez-Gomez, L., Baena, A., Aguillon, D., Villalba-Moreno, N. D., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02467-8 · Cited by 92 · cited 1×
“In vivo follow-up by PET imaging and postmortem studies revealed that the APOE3ch delayed AD onset for almost three decades beyond the expected age of onset [106].”
BackgroundThe role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease
Fontana, I. C., Kumar, A., & Nordberg, A. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00792-4 · Cited by 86 · cited 1×
“Aβ oligomer can upregulate α7-nAChR, by which it inhibits extra-cellular signal-related protein kinase 2 (ERK2), and subsequently suppress cAMP-response element binding protein (CREB) phosphorylation and downregulate BDNF, and finally results in impairment of LTP [255].”
BackgroundJackson, R. J., Keiser, M. S., Meltzer, J. C., Fykstra, D. P., Dierksmeier, S. E., Hajizadeh, S., Kreuzer, J., Morris, R., Melloni, A., Nakajima, T., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.024 · Cited by 86 · cited 1×
“APOE2 gene therapy has been shown to reduce Aβ deposition and improve markers of neuroinflammation and neurodegeneration [52].”
BackgroundIto, S., Ohtsuki, S., Kamiie, J., Nezu, Y., & Terasaki, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04938.x · Cited by 85
Yin, Y.-W., Li, J.-C., Wang, J.-Z., Li, B.-H., Pi, Y., Yang, Q.-W., Fang, C.-Q., Gao, C.-Y., & Zhang, L.-L. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.02.031 · Cited by 84
Self-citationPreparing for disease-modifying therapies in Alzheimer's disease
Belder, C. R. S., Schott, J. M., & Fox, N. C. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00274-0 · Cited by 83
Altered subcellular distribution of c-Abl in Alzheimer’s disease
Jing, Z., Caltagarone, J., & Bowser, R. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1062 · Cited by 83 · cited 1×
“In addition to Fyn, c-Abl is also present in NFTs and co-localizes with tau [351].”
BackgroundTau accumulation triggers STAT1‐dependent memory deficits by suppressing NMDA receptor expression
Li, X., Hong, X., Wang, Y., Zhang, S., Zhang, J., Li, X., Liu, Y., Sun, D., Feng, Q., Ye, J., et al. (2019) · The EMBO Reports · doi:10.15252/embr.201847202 · Cited by 81 · cited 1×
“Tau accumulation upregulates Janus kinase 2/signal transducer and activator of transcription 1 (JAK2/STAT1) signaling, and STAT1 can directly bind to the specific GAS element of GluN1, GluN2A, and GluN2B promoters or interact with STAT3 to suppress expression of NMDARs [306, 307].”
BackgroundSelf-citationCaspase-Cleaved Tau Impairs Mitochondrial Dynamics in Alzheimer’s Disease
Pérez, M. J., Vergara-Pulgar, K., Jara, C., Cabezas-Opazo, F., & Quintanilla, R. A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0385-x · Cited by 81 · cited 1×
“For example, tau truncated at Asp421 by caspases-3 and -6 damages microtubules and cytoskeleton [434, 436].”
BackgroundAPOE effects on regional tau in preclinical Alzheimer’s disease
Young, C. B., Johns, E., Kennedy, G., Belloy, M. E., Insel, P. S., Greicius, M. D., Sperling, R. A., Johnson, K. A., Poston, K. L., Mormino, E. C., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00590-4 · Cited by 80
Tau oligomers in cerebrospinal fluid in Alzheimer's disease
Sengupta, U., Portelius, E., Hansson, O., Farmer, K., Castillo‐Carranza, D., Woltjer, R., Zetterberg, H., Galasko, D., Blennow, K., & Kayed, R. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.382 · Cited by 77
The VCAM1–ApoE pathway directs microglial chemotaxis and alleviates Alzheimer’s disease pathology
Lau, S.-F., Wu, W., Wong, H. Y., Ouyang, L., Qiao, Y., Xu, J., Lau, J. H.-Y., Wong, C., Jiang, Y., Holtzman, D. M., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00491-1 · Cited by 70 · cited 1×
“A most recent study shows that IL-33 induces expression of vascular cell adhesion molecule-1 in microglia, which promotes microglial chemotaxis toward Aβ plaque-asso-ciated APOE, leading to Aβ clearance [90].”
BackgroundChandra, S., Di Meco, A., Dodiya, H. B., Popovic, J., Cuddy, L. K., Weigle, I. Q., Zhang, X., Sadleir, K., Sisodia, S. S., & Vassar, R. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00635-2 · Cited by 58 · cited 1×
“Gut microbiota plays an important role in controlling astrocyte activation, morphology, and recruitment to Aβ plaques [141].”
BackgroundA subset of senile dementia with high incidence of the apolipoprotein E ϵ2 allele
Ikeda, K., Akiyama, H., Arai, T., Sahara, N., Mori, H., Usami, M., Sakata, M., Mizutani, T., Wakabayashi, K., & Takahashi, H. (1997) · Annals of Neurology · doi:10.1002/ana.410410522 · Cited by 55
Quantification of Tau Protein Lysine Methylation in Aging and Alzheimer’s Disease
Huseby, C. J., Hoffman, C. N., Cooper, G. L., Cocuron, J.-C., Alonso, A. P., Thomas, S. N., Yang, A. J., & Kuret, J. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190604 · Cited by 54 · cited 1×
“The exact impact of lysine methylation on endogenous tau activity remains unclear [404].”
BackgroundVance, J. M., Farrer, L. A., Huang, Y., Cruchaga, C., Hyman, B. T., Pericak‐Vance, M. A., Goate, A. M., Greicius, M. D., Griswold, A. J., Haines, J. L., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26864 · Cited by 52 · cited 1×
“Reducing APOE4 in carriers is a therapeutic goal for AD [49].”
BackgroundSenile Plaques in an Aged Western Lowland Gorilla.
KIMURA, N., NAKAMURA, S., GOTO, N., NARUSHIMA, E., HARA, I., SHICHIRI, S., SAITOU, K., NOSE, M., HAYASHI, T., KAWAMURA, S., et al. (2001) · Experimental Animals · doi:10.1538/expanim.50.77 · Cited by 46
Marino, C., Perez‐Corredor, P., O'Hare, M., Heuer, A., Chmielewska, N., Gordon, H., Chandrahas, A. S., Gonzalez‐Buendia, L., Delgado‐Tirado, S., Doan, T. H., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13436 · Cited by 45 · cited 1×
“This resistance may be due to the reduced pathological interactions between APOE3Ch and heparan sulfate proteoglycans (HSPGs) [109].”
BackgroundTransmembrane protein 97 is a potential synaptic amyloid beta receptor in human Alzheimer’s disease
Colom-Cadena, M., Toombs, J., Simzer, E., Holt, K., McGeachan, R., Tulloch, J., Jackson, R. J., Catterson, J. H., Spires-Jones, M. P., Rose, J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02679-6 · Cited by 44 · cited 1×
“A recent study identified synaptic binding of transmembrane protein 97 with Aβ in the human AD brain, which might be involved in the synapse-associated toxicity of Aβ [256].”
BackgroundChemparathy, A., Le Guen, Y., Chen, S., Lee, E.-G., Leong, L., Gorzynski, J. E., Jensen, T. D., Ferrasse, A., Xu, G., Xiang, H., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.01.008 · Cited by 43 · cited 1×
“In contrast, APOE loss-of-function variants confer resistance to AD pathology [66].”
BackgroundOperto, G., Molinuevo, J. L., Cacciaglia, R., Falcon, C., Brugulat-Serrat, A., Suárez-Calvet, M., Grau-Rivera, O., Bargalló, N., Morán, S., Esteller, M., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101983 · Cited by 40
Aslam, M. M., Fan, K.-H., Lawrence, E., Bedison, M. A., Snitz, B. E., DeKosky, S. T., Lopez, O. L., Feingold, E., & Kamboh, M. I. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02170-4 · Cited by 39
When the infectious environment meets the AD brain
Ganz, T., Fainstein, N., & Ben-Hur, T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00559-3 · Cited by 39
Catumbela, C. S. G., Giridharan, V. V., Barichello, T., & Morales, R. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00369-7 · Cited by 37 · cited 1×
“The pathogens may also cause inflammatory damage by secreting toxins that can enter the brain through the circulatory system [117].”
BackgroundC/EBPβ/AEP Signaling Drives Alzheimer’s Disease Pathogenesis
Xiong, J., Zhang, Z., & Ye, K. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01025-w · Cited by 37
Sampognaro, P. J., Arya, S., Knudsen, G. M., Gunderson, E. L., Sandoval-Perez, A., Hodul, M., Bowles, K., Craik, C. S., Jacobson, M. P., & Kao, A. W. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00621-8 · Cited by 35
Langella, S., Barksdale, N. G., Vasquez, D., Aguillon, D., Chen, Y., Su, Y., Acosta-Baena, N., Acosta-Uribe, J., Baena, A. Y., Garcia-Ospina, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40775-z · Cited by 30
APOE ε4 is associated with decreased synaptic density in cognitively impaired participants
He, K., Li, B., Wang, J., Wang, Y., You, Z., Chen, X., Chen, H., Li, J., Huang, Q., Guo, Q., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13775 · Cited by 29
Self-citationThy1-ApoE4/C/EBPβ double transgenic mice act as a sporadic model with Alzheimer’s disease
Qian, Z., Wang, Z., Li, B., Meng, X., Kuang, Z., Li, Y., Yang, Y., & Ye, K. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02565-x · Cited by 28 · cited 1×
“In APOE4/C/EBPβ double transgenic mice, key AD pathologies appear in an age-dependent manner [65].”
BackgroundApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes
Eisenbaum, M., Pearson, A., Ortiz, C., Mullan, M., Crawford, F., Ojo, J., & Bachmeier, C. (2024) · Glia · doi:10.1002/glia.24469 · Cited by 25 · cited 1×
“Expression of APOE4 in astrocytes disrupts tau uptake, trafficking and clearance [101].”
BackgroundAβ-binding with alcohol dehydrogenase drives Alzheimer's disease pathogenesis: A review
Ye, Z., Liu, Y., Jin, X., Wu, Y., Zhao, H., Gao, T., Deng, Q., Cheng, J., Lin, J., & Tong, Z. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130580 · Cited by 23 · cited 1×
“Targeting the Aβ-ABAD interaction is emerging as a novel therapeutic strategy for AD [242, 243].”
BackgroundAPOE4/4 is linked to damaging lipid droplets in Alzheimer’s microglia
Haney, M. S., Pálovics, R., Munson, C. N., Long, C., Johansson, P., Yip, O., Dong, W., Rawat, E., West, E., Schlachetzki, J. C., et al. (2023) · doi:10.1101/2023.07.21.549930 · Cited by 20
Metadata
- Authors
- Liu, E., Zhang, Y., & Wang, J.-Z.
- Venue
- Translational Neurodegeneration
- Published
- 2024-09-04
- Volume
- 13
- Issue
- 1
- Pages
- 45-45
- ISSN
- 2047-9158 (ISSN-L)
- OpenAlex
- W4402242291
- Cited by
- 199
- References
- 284
- FWCI
- 47.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.